Laboratory of Neuroimmunology, Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Pediatr Allergy Immunol. 2022 Oct;33(10):e13863. doi: 10.1111/pai.13863.
Studies of anti-SARS-CoV-2 humoral and adaptive response in COVID-19 non-vaccinated pediatric convalescents are controversial and further evidence from the pediatric population are needed.
To elucidate SARS-CoV-2 humoral and memory B- and T-cells responses in pediatric convalescents as compared with the adult.
Blood samples were obtained from 80 non-vaccinated, IgG-positive, COVID-19 convalescents (age 8.0-61.0 years), 4.0 months from onset. Frequency of responders and magnitudes of SARS-COV-2 IgG, memory B-cells (MBC) and IFNg- and IL2-secreting memory T-cells (MTC) in response to immuno-dominant peptide pools in pediatric, young adults and middle-aged adults with onset age 8-18 years (N = 20), 19-39 years (N = 30) and 40-61 years (N = 30), respectively, were analyzed. SARS-CoV-2 IgG were detected by ELISA (Euroimmun, Germany). MBC, IFNg-, IL2- and IFNg+IL2-secreting MTC (IFNg-MTC, IL2-MTC and IFNg+IL2-MTC) were detected using FluoroSpot (Mabtech, Sweden).
MBC level was lower in pediatric as compared with the middle-aged adults (median 12.75 interquartile range [IQR] 4.27-33.7 and 32.0 IQR 6.0-124.2, respectively, p = .003). MBC level in young adults was lower than in middle-aged adults (median 18.5 IQR 1.7-43.8 and 32.0 IQR 6.0-124.2, respectively, p = .006). The level of IL2-MTC was lower in the pediatric group as compared with middle aged-adults (median 2.1 IQR 0-16.9 and 28.6 IQR 11-49.6, respectively, p < .03) and in young adults lower than in middle-aged adults (median 1.45 IQR 0-18.6 and 28.6 IQR 11-49.6, respectively, p = .02). In addition, the level of IFNg-MTC was lower in pediatric as compared with young adults (median 4.25 IQR 0.0-15.0 and 20.9 IQR 0-75.2, respectively, p = .05). The level of IgG was comparable between pediatric and both young and middle-aged adult groups (4.82 ± 2.95, 3.70 ± 2.65 and 4.9 ± 2.94, respectively, p > .34).
Non-vaccinated COVID-19 pediatric convalescents have lower adaptive immune responses than adults sustaining the recommendation for vaccination of the pediatric population.
关于 COVID-19 未接种疫苗的儿科康复者的抗 SARS-CoV-2 体液和适应性反应的研究存在争议，需要来自儿科人群的进一步证据。
阐明与成人相比，儿科康复者的 SARS-CoV-2 体液和记忆 B 细胞和 T 细胞反应。
从 80 名未接种疫苗、IgG 阳性、COVID-19 康复者（年龄 8.0-61.0 岁）中获得血液样本，发病后 4.0 个月。分析免疫显性肽池在儿科、年轻成年人和中年成年人中 SARS-COV-2 IgG、记忆 B 细胞（MBC）和分泌 IFNγ 和 IL2 的记忆 T 细胞（MTC）的应答频率和幅度，发病年龄分别为 8-18 岁（N=20）、19-39 岁（N=30）和 40-61 岁（N=30）。使用 ELISA（Euroimmun，德国）检测 SARS-CoV-2 IgG。使用 FluoroSpot（Mabtech，瑞典）检测 MBC、IFNγ-、IL2-和 IFNγ+IL2-分泌的 MTC（IFNγ-MTC、IL2-MTC 和 IFNγ+IL2-MTC）。
与中年成年人相比，儿科患者的 MBC 水平较低（中位数 12.75 四分位距[IQR] 4.27-33.7 和 32.0 IQR 6.0-124.2，分别，p=0.003）。年轻成年人的 MBC 水平低于中年成年人（中位数 18.5 IQR 1.7-43.8 和 32.0 IQR 6.0-124.2，分别，p=0.006）。与中年成年人（中位数 2.1 IQR 0-16.9 和 28.6 IQR 11-49.6，分别，p < 0.03）和年轻成年人（中位数 1.45 IQR 0-18.6 和 28.6 IQR 11-49.6，分别，p=0.02）相比，儿科组的 IL2-MTC 水平较低。此外，与年轻成年人相比，儿科患者的 IFNγ-MTC 水平较低（中位数 4.25 IQR 0.0-15.0 和 20.9 IQR 0-75.2，分别，p=0.05）。儿科患者与年轻和中年成年人组的 IgG 水平相当（分别为 4.82 ± 2.95、3.70 ± 2.65 和 4.9 ± 2.94，p > 0.34）。
未接种疫苗的 COVID-19 儿科康复者的适应性免疫反应低于成年人，这支持了为儿科人群接种疫苗的建议。
